← Leaderboards
Wei Zhou
Emory University
$6,934,396
Attributed
$8,610,375
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $863.7K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,610,375 · 7
By mechanism
R01$7,143,669 · 4
P01$1,031,335 · 1
P30$435,371 · 2
Top collaborators
- M Melissa Gilbert5 shared
- Adam I Marcus5 shared
Most similar at Emory University
Same institution · by research overlap
- Adam I Marcus$15,360,223
- Harold M. McClure$3,517,681
- Mary R Galinski$18,988,233
- M Melissa Gilbert$2,580,976
- Scott Wilkinson$86,696
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorStk11 GeneMalignant Neoplasm Of LungSignal TransductionMutationMutantGenesMolecularMutateBaseFutureCessation Of LifeMalignant NeoplasmsCancer EtiologyCancer CellMediatingDrug ResistanceCell LineNeoplastic CellNovel Therapeutic InterventionTumor Suppressor ProteinsNon-Small-Cell Lung CarcinomaResistance
Grant awards (27)
Targeting LKB1-null lung adenocarcinoma with innate immune system$433,754
R01 · FY2025 · CA · contact PI
Cell and Molecular Biology Research Program$258,891
P30 · FY2025 · CA · contact PI
Targeting LKB1-null lung adenocarcinoma with innate immune system$412,067
R01 · FY2024 · CA · contact PI
Cell and Molecular Biology Research Program$59,398
P30 · FY2024 · CA · contact PI
Targeting LKB1-null lung adenocarcinoma with innate immune system$431,156
R01 · FY2023 · CA · contact PI
Cell and Molecular Biology Research Program$57,939
P30 · FY2023 · CA · contact PI
Cancer Cell Biology$59,143
P30 · FY2022 · CA · contact PI
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers$356,850
R01 · FY2021 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$506,871
R01 · FY2020 · CA
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers$356,850
R01 · FY2020 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$491,665
R01 · FY2019 · CA
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers$346,144
R01 · FY2019 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$506,871
R01 · FY2018 · CA
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers$356,850
R01 · FY2018 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$504,281
R01 · FY2017 · CA
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers$356,850
R01 · FY2017 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$504,281
R01 · FY2016 · CA
Pro-Oncogenic Role of LKB1 in NSCLC$321,625
R01 · FY2015 · CA · contact PI
Pro-Oncogenic Role of LKB1 in NSCLC$311,976
R01 · FY2014 · CA · contact PI
Pro-Oncogenic Role of LKB1 in NSCLC$302,328
R01 · FY2013 · CA · contact PI
Pro-Oncogenic Role of LKB1 in NSCLC$321,625
R01 · FY2012 · CA · contact PI
Pro-Oncogenic Role of LKB1 in NSCLC$321,625
R01 · FY2011 · CA · contact PI
Altered LKB1/AMPK Signaling and Chemosensitivity in NSCLC$247,987
P01 · FY2010 · CA · contact PI
Altered LKB1/AMPK Signaling and Chemosensitivity in NSCLC$222,184
P01 · FY2009 · CA · contact PI
Altered LKB1/AMPK Signaling and Chemosensitivity in NSCLC$215,833
P01 · FY2008 · CA · contact PI
Altered LKB1/AMPK Signaling and Chemosensitivity in NSCLC$213,819
P01 · FY2007 · CA · contact PI
Altered LKB1/AMPK Signaling and Chemosensitivity in NSCLC$131,512
P01 · FY2006 · CA · contact PI